Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Objective: We studied whether the use of hydroxychloroquine (HCQ) for COVID‐19 resulted in supply shortages for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods: We used US claims data (IQVIA PHARMETRICS® Plus for Academics [PHARMETRICS]) and hospital electroni...

Full description

Bibliographic Details
Main Authors:	Mercadé‐Besora, N, Guo, Y, Du, M, Li, X, Ramírez‐Anguita, JM, Moreno, A, Valente, A, Villalobos, F, Cheng, IL, Carrasco‐Ribelles, LA, van Swieten, MMH, Merkelbach, M, Magoya, M, Lasalvia, P, Pericàs‐Pulido, P, Berg, P, Bosco‐Lévy, P, Lillini, R, Ribeiro, R, Bagga, TK, Ramella, V, Khalid, S, Mayer, MA, Leis, A, Jödicke, AM, Burn, E, Prieto‐Alhambra, D, Català, M, Prats‐Uribe, A
Format:	Journal article
Language:	English
Published:	Wiley 2024

Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Similar Items